History

Kenji Yamanouchi founded Yamanouchi Yakuhin Shokai in Osaka.
Changed the name to Yamanouchi Pharmaceutical Co., Ltd. in 1940, Moves the head office to Tokyo in 1942

Launched antibiotic drug "Josamycin"

Launched "Perdipine," an agent for the treatment of hypertension

Launched Gaster^®, an H2 reseptor antagonist diseases/gastritis
Currently sold in more than 100 countries

Established Yamanouchi Ireland Co., Ltd. in Europe
The first overseas production base for active pharmaceutical ingredients

Tsukuba laboratory completed

Acquired the pharmaceutical division of Royal Gist Brocades (Netherlands)

Launched Harnal^®
Currently sold in more than 90 countries

Established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China

Launched "Atorvastatin", an agent to treat hypercholesterolemia

Established Yamanouchi Pharma America, Inc. in the U.S.
Sales base of the company in the U.S.

Launched Vesicare^®, an agent for overactive bladder treatment, in Europe
Launched in the U.S. as well in 2005
OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.

Tomokichi Fujisawa founded Fujisawa Shoten in Osaka

Launched "Fujisawa Camphor" as a home-use insect repellent

Changed the company name to Fujisawa Pharmaceutical Co., Ltd.

Central Laboratory completed

Launched "Cefamezin," an antibiotic for injections
Proceeds to market it worldwide.

Established Fujisawa Pharmaceutical Corp. in the U.S.
The company's first business base in the U.S.

Opened a London Office, the company's first business base in Europe

Tsukuba Laboratory completed

Established Fujisawa Europe GmbH in Germany

Launched immunosuppressant Prograf^®
Currently sold in about 100 countries

Restructured the business in the U.S., founds Fujisawa Healthcare, Inc.

Launched "Tacrolimus", an agent to treat atopic dermatitis
Currently sold in about 60 countries

OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.

Launched Mycamine^®, an intravenous candin antifungal agent

Launched Vaprisol^®, an agent for the treatment of hyponatremia, in the U.S.
Sold Zephama shared to Daiichi Sankyo Co., Ltd.

Launched Vesicare^®, an agent for overactive bladder treatment, in Japan

Launched immunosuppresant Advagraf^® in Europe

Acquired Agensys, Inc

Completed the New Buildings in the Tsukuba Research Center

Launched Bonoteo^® Tablets in Japan for the Osteoporosis Treatment

Launched Vibativ^® (telavancin) in the United States

Launched "Formoterol+Budesonide Turbuhaler" in Japan for the treatment of Adult Bronchial Asthma

Acquired OSI Pharmaceuticals

Launched Betanis^® Tablet in Japan for the treatment of overactive bladder (OAB)

Launched Dificlir^® in Europe for the treatment of adults with Clostridium difficile infections (CDI)
Launched Kiklin^® Capsules in Japan for the treatment for Hyperphosphatemia

Launched Regnite^® Tablets in Japan for Restless Legs Syndrome

Launched Xtandi^® (enzalutamide) in the U.S. for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel

Launched Gonax^® (Degarelix Acetate) for Subcutaneous Injection in Japan for Treating Prostate Cancer
Launched Myrbetriq^® (mirabegron) in the U.S. for the treatment of overactive bladder (OAB)

Launched Argamate^® in Japan for the treatment of Hyperkalemia

Launched "Certolizumab Pegol" in Japan for the treatment of adult patients with rheumatoid arthritis

Relocated Global HQ building in Tokyo

Launched Acofide^® in Japan for Treating Functional Dyspepsia

Launched ASTAGRAF XL^® (tacrolimus extended-release capsules) in the U.S.

Launched Suglat^® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes

Launched Xtandi^® (enzalutamide) Capsules in Japan for Prostate Cancer Treatment